Balanced news tone
News Sentiment
6570 sentiment intelligence
Kyowa Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+1.0% over one week, +17.9% over four weeks, trend active, and materially above fair value.
Kyowa Kirin Co Ltd (4151) Stock, Price, News, Quotes, Forecast and Insights | MSN Money
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Kyowa Kirin Co Ltd (4151) Stock, Price, News, Quotes, Forecast and Insights | MSN Money
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 14 Jul 2026 06:24
- Source
- MSN
Kyowa Kirin Co Ltd (4151)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 06:09
- Source
- MSN
Kyowa Kirin outlines growth path as specialty pharma focus deepens
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 04 Jul 2026 07:00
- Source
- ad-hoc-news.de
Enterprise value to revenue forward of Kyowa Corporation Co. Ltd. – TSE:6570
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 21:47
- Source
- TradingView
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Apr 2026 07:00
- Source
- Market source
Kyowa Kirin discontinues rocatinlimab trials due to safety issues
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Mar 2026 08:00
- Source
- BioWorld News
Lupin enters into agreement to divest its stake in Kyowa to Unison - Lupin | Press Release
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 07 Feb 2026 20:04
- Source
- lupin.com
Kyowa's bet on Kura pays off as partners' oral med for AML subset wins FDA approval
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 13 Nov 2025 08:00
- Source
- Fierce Pharma
US FDA approves Kura-Kyowa's blood cancer therapy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- Reuters
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Sep 2025 07:00
- Source
- PR Newswire
Kyowa Kirin constructs drug manufacturing facility in Japan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Apr 2025 07:00
- Source
- Pharmaceutical Technology
Kyowa Kirin bolsters biomanufacturing footprint with $118m Japan plant
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Apr 2025 07:00
- Source
- BioProcess International
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Mar 2025 08:00
- Source
- PR Newswire
Orchard sells to Kyowa Kirin in gene therapy buyout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Oct 2023 07:00
- Source
- BioPharma Dive
Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Oct 2023 07:00
- Source
- STAT